IPCALABBSEIpca Laboratories LtdMediumNeutral
Announced Fri, 29 May · 13:59 IST

Re-appointment of Mr. Prashant Godha, as Executive Director

Management Changes View source PDF

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.9%1-day move
₹1570.10
prior close
₹1570.40
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3-0.0-0.8+1.2-5.9-3.9-1.2+3.2+4.9+4.1+1.3+4.6
Up moveDown movePending
AI summary

Ipca Laboratories held a Board meeting on May 29, 2026 that approved the audited financial results for FY 2025-26. Standalone revenue grew 9.9% to Rs. 7,337 Crores while consolidated revenue increased 7.9% to Rs. 9,646 Crores. The company reported strong profit growth with standalone profit before tax at Rs. 1,532 Crores (up 53%) and consolidated profit at Rs. 1,572 Crores (up 39%). Diluted EPS improved significantly to Rs. 44.64 from Rs. 25.65. The Board recommended a dividend of Rs. 6 per share (600%) for shareholder approval at the AGM with record date August 7, 2026. Additionally, Mr. Prashant Godha (51) was re-appointed as Executive Director for 5 years from August 16, 2026; he is related to Executive Chairman Premchand Godha and Managing Director Pranay Godha. Exceptional items included Rs. 30.42 Crores from new labour codes and impairment provisions.

Likely market impact

Positive signals from strong revenue and profit growth. The re-appointment of Mr. Godha maintains leadership continuity as he is part of the promoter family controlling the company.